Minimal clinically important differences for patient-reported outcome measures of fatigue in patients with COPD after pulmonary rehabilitation by Rebelo, Patrícia et al.
CONFIDENTIAL
If there is Online Only content that cannot be converted to a Word processing format, you may have to click 
the Supplemental Files icon on the menu bar in your Reviewer Center to access.
Minimal clinically important differences for patient-reported 
outcome measures of fatigue in patients with COPD after 
pulmonary rehabilitation.
Journal: CHEST
Manuscript ID CHEST-19-2122.R1
Article Type: riginal Research
Date Submitted by the 
Author: n/a
Complete List of Authors: Rebelo, Patricia; University of Aveiro, Lab 3R – Respiratory Research and 
Rehabilitation Laboratory, School of Health Sciences (ESSUA); University 
of Aveiro, iBiMED – Institute of Biomedicine, Department of Medical 
Sciences
Oliveira, Ana; West Park Healthcare Centre, Respiratory Medicine; 
McMaster University, School of Rehabilitation Science; University of 
Aveiro, Lab3R – Respiratory Research and Rehabilitation Laboratory, 
School of Health Sciences (ESSUA); University of Aveiro, iBiMED – 
Institute of Biomedicine, Department of Medical Sciences
Andrade, Lília; Centro Hospitalar do Baixo Vouga EPE, Pulmonology 
Department
Valente, Carla; Centro Hospitalar do Baixo Vouga EPE, Pulmonology 
Department
Marques, Alda; University of Aveiro, Lab 3R – Respiratory Research and 
Rehabilitation Laboratory, School of Health Sciences (ESSUA); University 
of Aveiro, iBiMED – Institute of Biomedicine, Department of Medical 
Sciences
Keywords: EXERCISE, Interpretability, Outcome measurement, Health Status, Clinical decision-making
 
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
CONFIDENTIAL
Abbreviations list
AECOPD – Acute exacerbation of Chronic Obstructive Pulmonary Disease 
AUC – Area under the curve
CAT – COPD Assessment Test
CI – Confidence interval
CIS-FS – Checklist of individual strength fatigue subscale
COPD – Chronic Obstructive Pulmonary Disease
ES – Effect size
FACIT-FS – Functional assessment of chronic illness therapy fatigue subscale
GRC – Global Rating of Change Scale
LR – Likelihood ratio
MCID – Minimal clinically important difference
MDC – Minimal detectable change
PR – Pulmonary rehabilitation
PROM - Patient-reported outcome measure
ROC – Receiver operating characteristic 
SD – Standard deviation
SEM – Standard error of measure
SGRQ – St. George’s Respiratory Questionnaire
Page 1 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
1
Text word count (max 2500): 3027
Abstract word count (max 250): 239
Running head (of 50 characters or less): Fatigue in COPD: quantifying improvement 
Minimal clinically important differences for patient-reported outcome measures of 
fatigue in patients with COPD after pulmonary rehabilitation.
Patrícia Rebelo, MSc1,2, Ana Oliveira, PhD1-4, Lília Andrade5, Carla Valente5, Alda Marques, 
PhD1,2
1Lab3R – Respiratory Research and Rehabilitation Laboratory, School of Health Sciences, 
University of Aveiro (ESSUA), Aveiro, Portugal
2iBiMED – Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, 
Aveiro, Portugal
3West Park Healthcare Centre, Toronto, ON, Canada
4School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
5Pulmonology Department, Centro Hospitalar do Baixo Vouga, Aveiro 
Corresponding author information: Alda Marques, 1Lab3R - Respiratory Research and 
Rehabilitation Laboratory, School of Health Sciences (ESSUA) and 2Institute of 
Biomedicine (iBiMED), University of Aveiro, Agras do Crasto - Campus Universitário de 
Santiago, Edifício 30, 3810-193 Aveiro, Portugal
Tel +351 234372462
Email amarques@ua.pt 
Conflict of interests’ statement: The authors report no financial, or non-financial, conflicts 
of interest in this work.
Funding information: This work, was funded by Fundo Europeu de Desenvolvimento 
Regional (FEDER) - Comissão Diretiva do Programa Operacional Regional do Centro, by 
Fundação para a Ciência e Tecnologia - FCT (SAICT-POL/23926/2016, PTDC/DTP-
PIC/2284/2014, PTDC/SAU-SER/28806/2017, UID/BIM/04501/2019) and by Programa 
Operacional Competitividade e Internacionalização (COMPETE), through COMPETE 2020 
(POCI-01-0145-FEDER-016701, POCI-01-0145-FEDER-007628, POCI-01-0145-
FEDER-028806).
Notation of prior abstract publication/presentation: 
 European Respiratory Society (ERS) International Congress, 28th September – 2nd 
October 2019, Madrid, Spain
 World Confederation of Physical Therapy Congress, 10th -13th May 2019, Genève, 
Switzerland
Page 2 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
2
1 ABSTRACT:
2 Background: Fatigue is a burdensome and prevailing symptom in patients with chronic 
3 obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) improves fatigue 
4 however, interpreting when such improvement is clinically relevant is challenging. Minimal 
5 clinically important differences (MCIDs) for instruments assessing fatigue are warranted to 
6 better tailor PR and guide clinical decisions. We estimated MCIDs for the functional 
7 assessment of chronic illness therapy-fatigue subscale (FACIT-FS), the modified-FACIT-
8 FS and the checklist of individual strength-fatigue subscale (CIS-FS), in patients with COPD 
9 after PR.
10 Methods: Data from patients with COPD who completed a 12-weeks community-based PR 
11 programme were used to compute the MCIDs. The pooled MCID was estimated by 
12 calculating the arithmetic weighted mean, resulting from the combination of anchor (weight-
13 2/3) and distribution-based (weight-1/3) methods. Anchors were patients’ and 
14 physiotherapists’ global rating of change scale, COPD assessment test, St. George’s 
15 respiratory questionnaire (SGRQ) and exacerbations. To estimate MCIDs we used mean 
16 change, receiver operating characteristic curves and linear regression analysis for anchor-
17 based approaches, and 0.5*standard deviation, standard error of measurement 
18 (SEM),1.96*SEM and minimal detectable change for distribution-based approaches.
19 Results: Fifty-three patients with COPD (79%male, 68.4±7.6years, FEV148.7±17.4%predicted) 
20 were used in the analysis. Exacerbations, the SGRQ-impact and the SGRQ-total scores 
21 fulfilled the requirements to be used as anchors. Pooled MCIDs were 4.7 for FACIT-FS, 3.8 
22 for the modified-FACIT-FS and 9.3 for the CIS-FS.
23 Conclusion: The MCIDs proposed in this study can be used by different stakeholders to 
24 interpret PR effectiveness.
25 Clinical trial registration: NCT03799666 on ClinicalTrials.gov
26 Keywords:  *Exercise *Interpretability *Outcome measurement *Health status * clinical 
27 decision-making
28
29
30
Page 3 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
3
31 INTRODUCTION: 
32 Chronic obstructive pulmonary disease (COPD) is highly symptomatic.1 Although dyspnoea 
33 is the symptom most commonly reported,1 fatigue has been recognised to affect around 50 
34 to 70% of patients with COPD.2,3 Fatigue is a multi-dimensional and disabling symptom 
35 defined as an overwhelming feeling of tiredness and drain of energy.4,5 It negatively 
36 influences patients’ physical, cognitive, psychological and social functioning,4,6-8 leads to 
37 limited daily functioning and reduced health-related quality of life.3,8-10 Fatigue severely 
38 impacts on COPD prognosis, being closely associated to exacerbations rate and an 
39 independent predictor of mortality.10-13 
40 Pulmonary rehabilitation (PR) is a fundamental intervention to manage COPD, with known 
41 cost-effectiveness in fatigue reduction.1,8,14-18 However, the interpretation of PR effects on 
42 fatigue remains a challenge due to the lack of well-established minimal clinically important 
43 differences (MCID) of patient-reported outcome measures (PROMs) that assess fatigue.19-
44 21 MCIDs establish thresholds for clinical meaningfulness, i.e., determine which is the 
45 smallest change in a PROM score that will be perceived as an important improvement for 
46 the patient.19,21,22 MCIDs for fatigue-related PROMs will establish a therapeutic threshold 
47 for PR effectiveness and guide clinical decision-making in the management of patients with 
48 COPD.23-25 A wide variety of methods can be used to estimate MCIDs,23,24,26-28 among which 
49 the following two are distinguished: anchor-based methods, which use an external criterion 
50 (e.g., self-reported opinion or clinicians judgements) to provide clinical meaning;27,29 and 
51 distribution-based methods, that add statistical significance by expressing change scores 
52 according to the sample variability and measurement precision.27,30 Although the importance 
53 of anchor-based approaches in comparison to distribution methods has been advocated,23,27 
54 both methodologies present limitations, thus, the recommendation is to triangulate both 
55 methods.27,28 
56 We determined the MCID of three PROMs commonly used to assess fatigue in patients with 
57 COPD, the functional assessment of chronic illness therapy fatigue subscale (FACIT-FS),31 
58 the modified-FACIT-FS32 and the checklist of individual strength fatigue subscale (CIS-
59 FS).4
60 MATERIALS AND METHODS: 
61 Study design and population 
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62 This observational prospective study is integrated into a larger trial (NCT03799666), with 
63 ethical approval from the Ethics Committee for Health of the Administração Regional de 
64 Saúde do Centro (Ref. 73/2016) and from the National Committee for Data Protection (no. 
65 7295/2016). All participants signed an informed consent.
66 Patients diagnosed with COPD,1 who completed a 12-weeks community-based PR 
67 programme, between January and July 2019, in 6 primary healthcare centres and in the 
68 Respiratory Research and Rehabilitation laboratory (Lab3R) at the School of Health 
69 Sciences, University of Aveiro, were included. Exclusion criteria included the presence of 
70 other respiratory diseases or significant cardiovascular, neurological or musculoskeletal 
71 disease which limited patients’ participation in PR. The PR programme consisted of exercise 
72 training sessions twice a week and education and psychosocial sessions once every two 
73 weeks, with two of them targeting specifically the management of fatigue: i) management 
74 of symptoms and strategies of energy conservation and ii) sleep disorders and management 
75 of stress and anxiety. Further information regarding the intervention and education and 
76 psychosocial contents has been previously published.33,34 Only participants who attended at 
77 least 8 of the 12-weeks of PR were included.1 
78 A sample size of at least 50 participants is required to determine the MCID of a PROM.35,36  
79 Since the drop-out rates during PR programmes range from 20 to 30%,37,38 we aimed to 
80 recruit 65 participants. 
81 Data collection
82 Sociodemographic, anthropometric and clinical data were obtained to characterise the 
83 sample. The Charlson Comorbidity Index39 was used to score the severity of comorbid 
84 conditions. The remaining outcome measures were assessed before (T0) and after PR (T1). 
85 Impact of the disease was assessed with the COPD assessment test (CAT)40 and health-
86 related quality of life with the St. George’s respiratory questionnaire (SGRQ).41
87 The FACIT-FS is a multi-dimensional 13-item questionnaire assessing tiredness, weakness 
88 and difficulty in handling daily activities due to fatigue, over the previous 7 days.12,31 Each 
89 item has a 5-points Likert scale (from “not at all” to “very much”), and scores range from 0 
90 to 52, with higher scores indicating less fatigue.31,42 Patients scoring below the cut-off point 
91 of 43 points were considered to have clinically relevant fatigue.43 The FACIT-FS has shown 
92 high internal consistency32 and test-retest reliability,44 and good concurrent and 
93 discriminating validity32,45 in patients with COPD. A modified version of FACIT-FS, 
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94 adapted to patients with COPD, has been proposed.32 The modified-FACIT-FS  has 9 items 
95 and scores range from 0 to 36 points.32 
96 The CIS-FS4 was used to evaluate the fatigue experience. The CIS-FS is an 8-statements 
97 self-reported measure, with a period recall of two weeks, where each item is scored on a 7-
98 point Likert scale.4 Total scores range from 8 to 56, and 3 subgroups can be categorised: 
99 normal fatigue (≤26 points), mild fatigue (27-35 points) and severe fatigue (≥36 points).46 
100 The CIS-FS has shown high internal consistency and test-retest reliability, good concurrent 
101 and criterion validity46 and ability to detect change in subjective fatigue.2,47-49 
102 The global rating of change scale (GRC) is a simple, retrospective and numerical analogue 
103 scale50 that asks patients to make a judgement regarding their perceived fatigue after PR and 
104 to compare it with the initial assessment. It was administered only after PR, using an 11-
105 point Likert scale ranging from -5 (much worse) to +5 (much better) (supplementary 
106 material).50
107 Statistical analysis
108 Data analysis was performed with IBM SPSS Statistics 24, and plots were designed with 
109 GraphPad Prism 7 and MetaXL 5.3. Paired t-test were used to test significance of changes 
110 in PROMs from T0 to T1. Floor and ceiling effects were checked and deemed inexistent if 
111 less than 15% of the patients scored at the bottom or top of the questionnaires.51 Outliers 
112 were checked, i.e., inspection of extreme points in plotted graphs from the studied variables, 
113 and excluded if present.52 
114 MCIDs were established through the combination of anchor-based and distribution-based 
115 methods for the FACIT-FS, modified-FACIT-FS and CIS-FS. 24,27 
116 Anchor-based methods
117 The following measures were explored for their adequacy to be used as anchors:
118 i) Patients referencing: the GRC was used to classify patients’ perception of change in 
119 fatigue. Significant changes were considered for the GRC higher than 2.50
120 ii) Physiotherapists referencing: the GRC was used to ask the physiotherapists running 
121 the PR programmes about their perception regarding patients’ changes in fatigue. 
122 Significant changes were considered for the GRC higher than 2.50
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123 iii) Questionnaire referencing: changes in CAT and SGRQ were used as external 
124 criterions to determine the CIS-FS and FACIT-FS MCIDs. The MCIDs for the CAT 
125 (2 points)53 and for the SGRQ (4 points)54 were used to distinguish between patients 
126 who improved from those who did not improve their fatigue symptoms.
127 iv) Criterion referencing: AECOPD are considered major health events1 and are 
128 correlated to worse PROM scores, thus, their occurrence during PR was used as an 
129 anchor.25 
130 Correlations between the potential anchors and each fatigue-related PROM were explored 
131 using Pearson or point-biserial correlation coefficients. For patients, physiotherapists and 
132 questionnaire referencing, significant and moderate correlations (r≥0.3) were established as 
133 criteria to proceed with the calculation of the MCIDs using anchor-based methods.27 Then, 
134 three statistical methods were used to compute the MCID: i) mean change in the PROM 
135 score (between T1 and T0) for patients who reached the anchor MCID;22,24 ii) receiver 
136 operating characteristic (ROC) curves and the corresponding likelihood ratio (LR) 
137 (interpreted according to McGee),55 calculated with the dichotomous variable, i.e., those 
138 who achieved or not the MCID of the anchor [an area under the curve (AUC) was considered 
139 adequate if statistically significant and greater than 0.7; the optimal cut-off point was set as 
140 the point where specificity and sensitivity were both optimised, i.e., the closest point to the 
141 left corner]55 and iii) linear regression analysis, using the Enter method, where the change 
142 in the fatigue PROMs was used as the dependent variable, and the change score of the anchor 
143 was considered the independent variable. 
144 Regarding criterion referencing, the presence of significant differences in fatigue baseline 
145 scores between patients who experienced an exacerbation and those who did not was the 
146 criteria to proceed with the MCID calculation. Independent t-tests were used to explore 
147 differences and when present, the absolute difference was considered the MCID25,56 
148 Afterwards, ROC statistics were used to test the PROMs discriminating ability to anticipate 
149 the occurrence of an AECOPD. 
150 Distribution-based methods
151 The distribution-based methods used to determine the MCID were: 
152 i) 0.5 times standard deviation (SD) at the baseline;26
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153 ii) standard error of measurement (SEM), calculated as SEM=SDbaseline√(1-r), where 
154 r is the test-retest reliability coefficient;21
155 iii) 1.96 times SEM;23,28
156 iv) minimal detectable change (MDC),26,57 calculated as MDC=1.96*SEM*√2;
157 v) effect size (ES) through ES=(meanafterPR–meanbaseline)/
158 . The ES thresholds were ≥0.2 for small, ≥0.5 for (SD2afterPR + SD2baseline)/2
159 medium and ≥0.8 for large.57 
160 Pooled MCID
161 There are no guidelines on how to weight anchor- and distribution-based approaches, 
162 therefore, based on the authors’ best judgement and on previous work,58,59 we decided to 
163 attribute 2/3 to anchor-based and 1/3 to distribution-based methods. To pool the final MCID 
164 we calculated the arithmetic weighted mean. The MCIDs generated from the different 
165 methods were entered into the MetaXL 5.3 to create the MCIDs’ plots. The percentage of 
166 change of the pooled MCID in relation to the fatigue-related PROMs was also calculated. 
167 Previous studies have suggested that MCIDs which fell within the range of 6 to 10% of the 
168 total score,24 correspond to the desirable ES for MCID, i.e., 0.2 to 0.5.24,27,57 The ES derived 
169 from the pooled MCID were calculated using the ESformula: MCIDES = 
170 MCIDpooled/ . (SD2afterPR + SD2baseline)/2
171 RESULTS: 
172 A flow diagram of the recruited and included patients is provided in Figure 1.
173 (Please insert Figure 1 here)
174 After outliers’ assessment, five participants were excluded since in boxplot analysis, they 
175 presented extreme scores in FACIT-FS and SGRQ-total change scores. Baseline 
176 characteristics of the included sample and of the outliers were not statistically different 
177 (p>0.05). Included patients and drop-outs presented similar baseline characteristics (Table 
178 1).
179 (Please insert Table 1 here)
180 After PR, significant improvements were found in all PROMs (Table 2): 86.8% of 
181 participants perceived improvements in their fatigue (GRC: 3.0 [2.0-4.0]) and 
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182 physiotherapists also considered that 86.8% of patients improved (3.0, [2.0-4.0]). No 
183 ceiling/floor effects were found for the FACIT-FS, modified-FACIT-FS and CIS-FS. 
184 (Please insert Table 2 here)
185 Minimal clinically important differences
186 Anchor-based methods
187 Changes in the FACIT-FS and modified-FACIT-FS correlated significantly and moderatly 
188 with changes in the SGRQ-total (r=-0.330; r=-0.439), -impact scores (r=-0.409; r=-0.474) 
189 and with AECOPD (rpb=-0.277; rpb=-0.274). A significant correlation between changes in 
190 modified-FACIT-FS and SGRQ-ativities scores was also present, however, it was not 
191 considered since it was inferior to 0.3 (r=-0.288). Changes in the CIS-20 FS correlated only 
192 with AECOPD (rpb=0.323), therefore, the remaining anchors were not further analysed. All 
193 correlations are presented in e-Table 1.
194 Questionnaire referencing
195 MCIDs for the FACIT-FS derived from the mean change methods were 5.7 points using the 
196 SGRQ-impact and 4.9 points using the SGRQ-total whereas for the modified-FACIT-FS 
197 were 4.4 points using SGRQ-impact and 3.9 using SGRQ-total (Table 3). Mean change 
198 results for all the explored anchors can be found in e-Table 2 and e-Table 3.
199 The AUCs generated for either FACIT-FS and modified-FACIT-FS using the SGRQ-
200 impact/total did not fulfill the requirements, thus, ROC statistics were not used. 
201 Using linear regression, the estimated MCIDs for the FACIT-FS were 3.4 (SGRQ-impact) 
202 and 3.2 (SGRQ-total) points and  for the modified-FACIT-FS were 2.3 points using SGRQ-
203 impact and 1.9 points using SGRQ-total (Figure 2). 
204 (Please insert Figure 2 here)
205 Criterion Referencing
206 Mean change method applied for criterion referencing yielded a MCID of 6.4 (95%CI 1.2 
207 to 11.6; p=0.044) points for the FACIT-FS; of 4.7 (95%CI 0.1 to 9.3; p=0.047) points for 
208 the modified-FACIT-FS; and of 9.6 points (95%CI 2.5 to 16.0; p=0.018) for CIS-FS (e-
209 Table 4).
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210 The AUCs generated for all fatigue PROMs were able to distinguish between patients who 
211 experienced an AECOPD and those who did not (FACIT-FS: AUC=0.71; 95%CI 0.58 to 
212 0.85; p=0.021/ modified-FACIT-FS: AUC=0.73; 95%CI 0.59 to 0.86; p=0.015/ CIS-FS: 
213 AUC=0.72; 95%CI 0.57 to 0.87; p=0.019)(e-Figure 1). According to the ROC analysis, 
214 patients scoring below 32 points on the FACIT-FS or above 43.5 points on the CIS-FS had 
215 a LR of 2.2 (sensitivity=68%; specificity=69%). Cut-off point found for the modified-
216 FACIT-FS  was 19.5 points, with a LR of 2.5 (sensitivity=73%; specificity=69%).
217 Distribution-based methods
218 Distribution-based methods for the FACIT-FS, modified-FACIT-FS and CIS-FS are 
219 presented in Table 3. 
220 Pooled MCID
221 Pooled MCIDs were  4.7 points for the FACIT-FS,  3.8 for the modified-FACIT-FS and  9.3 
222 points for CIS-FS (Figure 3). Overall MCID pooled statistics are presented in Table 3.
223 (Please insert Figure 3 here)
224 (Please insert Table 3 here)
225 DISCUSSION:
226 This study found pooled MCIDs of 4.7 points for the FACIT-FS, 3.8 points for the modified-
227 FACIT-FS and 9.3 points for CIS-FS, following a PR programme in patients with COPD.
228 Nearly 80% of our sample reported fatigue symptoms, surpassing the 50 to 70% reported in 
229 previous literature.2,3,11,60 These findings call for attention to the tremendous impact and 
230 burden of fatigue in COPD, emphasising the importance of its routine assessment and the 
231 need for tailoring therapies to target fatigue. Our results showed significant improvements 
232 in FACIT-FS, modified-FACIT-FS and CIS-FS following a community-based-PR 
233 programme, highlighting the effectiveness and the key role of this comprehensive 
234 intervention in managing fatigue.2,16,18
235 MCIDs are recognised to be disease-specific23 and, to our best knowledge, this is the first 
236 study to establish MCIDs for both FACIT-FS versions and CIS-FS in patients with COPD. 
237 For the original-FACIT-FS, the MCID has been previously determined in other populations, 
238 with our estimation being similar to the one reported for rheumatoid arthritis (i.e., 3-4 
239 points),61 but smaller than the estimated for the systemic lupus erythematosus (i.e., 5.9 
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240 points).62 These differences are likely to be explained by the dissimilarities among 
241 populations and methodologies (longitudinal and within-patient differences vs. cross-
242 sectional and between patient-differences). Although a MCID of 10 points has been reported 
243 for the CIS-FS,2 no information, or reference, regarding its calculation is provided limiting 
244 comparisons between studies. 
245 MCIDs were computed using different approaches and integrating a wide range of anchor- 
246 and distribution-based methods. It is known that MDC yield large estimates and tend to 
247 overestimate MCIDs.23,63 Previous research have classified MDC as a benchmark for 
248 moderate to large change, warning that MCIDs could be smaller than MDC.23,63 These 
249 discrepancies enhance the need to combine anchor-based methods (weighting 2/3), which 
250 provide clinical meaning, and distribution-based methods (weight 1/3), which add statistical 
251 significance,23,27 as previously recommended.24,27 
252 Within the multiple anchor-based approaches used, only the SGRQ and the occurrence of 
253 AECOPD fulfilled the criterion to proceed with the MCID calculation, with the latter 
254 yielding larger estimations. Regarding either patients’ or physiotherapists’ GRC, it is 
255 noticeable that most patients/physiotherapists perceived improvements in fatigue, thus the 
256 variability of data was reduced, which is known to limit the power of correlations.64 
257 Moreover, another hypothetical reason for the lack of correlations is the well-known recall 
258 and administration bias associated to  the GRC.24,50,65 Fatigue is a complex, multifaceted and 
259 dynamic phenomenon,5 and PROMs focus specifically on the perceived fatigability, thus, 
260 do not fully portray fatigue. This complexity might also have impacted our correlations. 
261 Disparities among physiotherapists’ GRC and the fatigue PROMs sustain the poor 
262 physician-patient concordance previously stated.66 
263 The impact of fatigue on health status and quality of life is irrefutable.2,10,11,32 Previous 
264 associations between these outcomes2,32 highlight the importance of the SGRQ to determine 
265 fatigue-related MCIDs. The absence of correlations among the CIS-FS and the SGRQ 
266 dimensions might be explained by the conceptual differences between the fatigue PROMs. 
267 While the CIS-FS focuses specifically on the subjective experience of fatigue,4 FACIT-FS 
268 integrates two components of fatigue: experience of fatigue and impact of fatigue,67 
269 probably, the latter is more intimately related to the SGRQ impact-dimension and 
270 consequently, to the total-dimension.32 CAT assesses several respiratory symptoms, and 
271 only one item is directly related to fatigue (energy). Instead of the CAT-total score, which 
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272 failed to capture changes in fatigue, it would have been interesting to use as an anchor the 
273 CAT-energy question. However, this was not possible, as the MCID for single CAT-items 
274 is not established.
275 Similar to previous research,11,12 our study, further established the role of fatigue as a 
276 prognostic measure for AECOPD, showing that patients scoring below 32 points on the 
277 FACIT-FS, below 19.5 points on the modified-FACIT-FS and over 43.5 on the CIS-FS have 
278 around 15% increased probability of having and exacerbation (LR from 2.2 to 2.5).55 
279 According to our results, all fatigue PROMs used have similar prediction abilities to 
280 distinguish between patients who experienced an AECOPD from those who did not. Thus, 
281 these tree questionnaires seem to be equally valuable to predict a patient’s exacerbation risk 
282 and to adjust the PR programme accordingly (e.g., by further enhancing the education on 
283 prevention of exacerbations).68 
284 Nevertheless, this study also presents some limitations that should be acknowledged. First, 
285 the PROMs used as referencing questionnaires, i.e., CAT and SGRQ, do not assess fatigue 
286 specifically. To the authors’ best knowledge, the chronic respiratory questionnaire is the 
287 only PROM that specifically targets fatigue and has a MCID established for patients with 
288 COPD,69 however it could not be used in this study, as it is not culturally adapted for the 
289 Portuguese population. Second, our sample was mainly composed by GOLD B patients, 
290 therefore, the external validity of our study might be reduced. MCIDs should correspond to 
291 a 6 to 10% change in the PROMs scale and to an ES between 0.2 to 0.5.24,27,57 The MCID 
292 found for CIS-FS corresponded to an ES of 0.7 and 19% change, thus, it may have been 
293 overestimated. It is worth noting that, even if nor ceiling or floor effects were present, our 
294 sample presented high baseline levels of fatigue, leading to greater room for improvement 
295 with treatment, and thus higher MCIDs.23,24,26,70 The fact that only the criterion anchor and 
296 distribution-based methods were used to compute the MCID for CIS-FS, could have also 
297 contributed to overestimate the result. Our overall sample size was not enough to perform 
298 sub-analysis according to baseline fatigue or disease severity. This study included 
299 exclusively the physiotherapists GRC, thus providing a limited insight into patients’ fatigue, 
300 as PR is a multidisciplinary intervention. Future studies including a Delphi Method would 
301 be useful to integrate different stakeholders’ perspectives.27 A consensus between 
302 worldwide experts in MCIDs would be extremely helpful to confidently establish the 
303 weights assigned to either anchor- and distribution-based approaches. More studies with 
304 larger samples are required to control for these factors and further validate our estimations. 
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305 CONCLUSIONS:
306 The present study determined that changes of 4.7 on the FACIT-FS, 3.8 on the modified-
307 FACIT-FS and 9.3 on the CIS-FS represent clinically relevant improvements in fatigue after 
308 PR in patients with COPD. These MCIDs should be interpreted accordingly to each patient 
309 specificities and incorporated into clinical practice to guide different stakeholders in the 
310 decision-making process. 
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527 Table 1: Sample characterisation (n=70).
Characteristics Patients included
n=53 (75.7%)
Drop-outs
n=17 (24.3%)
p-value
Age, years 68.4±7.6 67±11.3 0.568
Gender, male n (%) 42 (79.2) 12 (70.6) 0.460
BMI, kg/m2 25.6±4.3 27.2±4.8 0.217
Smoking status, n (%)
Current
Former
Never
9 (17)
35 (66)
9 (17)
6 (35.3)
7 (41.2)
4 (23.5)
0.638
Packs/year 40.5 [26.4-64] 22 [13.3-50.4] 0.057
Exacerbations/year1, n 1 [0-1] 1 [0-2] 0.139
AECOPD hospitalisations1, n (%) 4 (7.5) 4 (23.5) 0.072
Duration of hospitalisations, days 8.2±7.1 10.4±9.4 0.606
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COPD-related emergencies1, n (%) 18 (34) 7 (41.2) 0.589
Lung function (post-bronchodilator)
FEV1, l 1.3±0.5 1.4±0.5 0.404
FEV1, %predicted 48.1±17.4 56.5±19.6 0.101
FEV1/FVC, % 49.1±14.1 55.9±13 0.077
GOLD stages, n (%)
I
II
III
      IV
5 (9.4)
19 (35.8)
23 (43.4)
6 (11.3)
2 (11.8)
7 (41.2)
7 (41.2)
1 (5.9)
0.905
GOLD groups, n (%)
A
B
C
D
8 (15.1)
34 (64.2)
0 (0)
11 (20.8)
4 (23.5)
6 (35.3)
0 (0)
7 (41.2)
0.106
CCI, n (%) 0.389
Mild (1-2 points) 7 (13.2) 1 (5.9)
Moderate (3-4 points) 30 (56.6) 8 (47.1)
Severe (≥5 points) 16 (30.2) 8 (47.1)
Medication, n (%) 
Bronchodilators
SABA 7 (13.2) 1 (5.9) 0.360
SAMA 2 (3.8) 0 (0) 0.393
LABA 6 (11.3) 5 (29.4) 0.102
LAMA 16 (30.2) 10 (58.8) 0.065
LAMA/LABA combination 16 (30.2) 4 (23.5) 0.597
ICS 9 (17) 1 (5.9) 0.226
ICS/LABA combination 23 (43.3) 7 (41.2) 0.872
ICS/LABA/LAMAcombination 1 (1.9) 0 (0.0) 0.273
LTRA 2 (3.8) 2 (11.8) 0.217
Xanthines 10 (18.9) 2 (11.8) 0.499
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Expectorants 5 (9.4) 1 (5.9) 0.649
Antibiotics 1 (1.9) 0 (0) 0.606
mMRC, points 2 [1-3] 2 [1-3] 0.733
CAT, points 16.9±7.5 16.2±9.2 0.736
SGRQ, points
Symptoms 55±20.5 45.8±20.1 0.112
Activities 64.8±20.9 50.3±27.8 0.060
Impact 36.6±19.8 27.8±19.1 0.114
Total 48.2±18.6 37.7±19.8 0.050
FACIT-FS, points 33.3±10 37.7±12.8 0.151
No relevant fatigue (>43), n (%) 19 (17) 5 (29.4)
Relevant fatigue (≤43), n (%) 44 (83) 12 (70.6)
0.214
Modified-FACIT-FS 21.2±7.4 22.7±7.7 0.496
CIS-FS, points 36.9±12.8 32.7±13.9 0.258
Normal fatigue (≤26), n (%) 9 (17) 6 (35.3)
Mild fatigue, (27-35), n (%) 12 (22.6) 5 (29.4)
Severe fatigue (≥36), n (%) 32 (60.4) 6 (35.3)
0.153
528 Notes: Values are presented as mean±standard deviation or median [interquartile range], unless otherwise stated. 1in the past-year; * 
529 p<0.05
530 Legend: PR – pulmonary rehabilitation; BMI – body mass index; AECOPD – acute exacerbation of chronic obstructive pulmonary 
531 disease; FEV1 – forced expiratory volume in one second; FVC – forced vital capacity; GOLD - Global Initiative for Chronic Obstructive 
532 Lung Disease; CCI – Charlson comorbidity index; SABA – short-acting beta-agonists; SAMA – short-acting muscarinic antagonist; 
533 LABA – long-acting beta-agonists; LAMA – long-acting muscarinic antagonist; ICS – inhaled corticosteroid; LRTA – leukotriene receptor 
534 antagonist; mMRC – modified medical research council questionnaire; CAT – COPD assessment test; SGRQ – St George’s Respiratory 
535 Questionnaire; FACIT-FS - Functional assessment of chronic illness therapy fatigue subscale; CIS-FS - Checklist of individual  strength 
536 fatigue subscale.
537
538
539
540
541
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542 Table 2: Patient-reported outcome measures before and after the community-based 
543 pulmonary rehabilitation programme (n=53).
PROM (points) Baseline Post-PR △ 95% CI p-value ES
CAT 16.9±7.5 13.0±6.9 -3.9±6.7 -5.8 to -2.0 <0.001* -0.54
SGRQ 
Symptoms 55±20.5 41.1±20.5 -13.9±21.5 -19.8 to -7.9 <0.001* -0.68
Activities 64.8±20.9 57.8±23.5 -7.0±11.6 -10.2 to -3.8 <0.001* -0.31
Impact 36.6±19.8 30.4±18.7 -6.2±12.0 -9.5 to -2.8 <0.001* -0.32
Total 48.2±18.6 40.6±18.1 -7.6±10.4 -10.5 to -4.7 <0.001* -0.41
FACIT-FS 33.3±10 36.9±8.8 3.7±7.1 1.7 to 5.6 <0.001* 0.38
Modified-FACIT-
FS 21.2±7.4 24.0±6.9 2.7±5.5 1.2 to 4.3 0.001 0.38
CIS-20 FS (n=52) 36.9±12.8 31.1±13.4 -5.8±10.2 -8.7 to -3.0 <0.001* -0.44
544 Notes: Values are presented as mean±standard deviation. *p<0.05
545 Legend: PROM – Patient-reported outcome measure; PR – pulmonary rehabilitation; △ – mean change; ES – Effect sizes: 95%CI – 
546 95% confidence interval; CAT – COPD assessment test; SGRQ – St George’s Respiratory Questionnaire; FACIT-FS – Functional 
547 assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength fatigue subscale.
548
549
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563 Table 3: Anchor and distribution-based methods used to compute the minimal clinically 
564 important difference of fatigue patient-reported outcome measures.
565
566 Notes: Values are presented as mean and 95% confidence intervals. % of change was computed within each scale range. The MCID ES 
567 are compute as the MCID value divided by the pooled SD.  
568 Legend: FACIT-FS – Functional assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength 
569 fatigue subscale; SGRQ – St George’s Respiratory Questionnaire; ROC – Receiver operating characteristic curves; SD – standard 
570 deviation; SEM – standard error of measurement; MDC – minimal detectable change; ES – effect size; MCID - minimal clinically 
571 important difference.
572
573
574
FACIT-FS Modified-FACIT-
FS
CIS-FS
Mean change 5.7 (3.3 to 8.1) 4.4 (2.4 to 6.4) -
ROC - - -SGRQ-Impact
Linear regression 3.4 (2.1 to 4.7) 2.3 (1.2 to 3.3) -
Mean change 4.9 (2.5 to 7.2) 3.9 (2.0 to 5.9) -
ROC - - -SGRQ-Total
Linear regression 3.2 (1.7 to 4.6) 1.9 (0.7 to 3.1) -
AECOPD Mean change 6.4 (1.2 to 11.6) 4.7 (0.1 to 9.3) 9.6 (3.2 to 15.9)
0.5SD 4.3 3.7 6.4
SEM 2.6 2.2 5.0
1.96SEM 5.1 4.4 9.7
MDC 7.2 6.2 13.8
ES 0.42 0.38 -0.44
Pooled MCID 4.7 3.8 9.3 
% of change 9.1 10.6 19.3
MCID ES 0.5 0.5 0.7
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575 FIGURE LEGEND: 
576 Figure 1: Flow diagram of participants recruited and included in the study. COPD – Chronic 
577 obstructive pulmonary disease; PR – pulmonary rehabilitation; AECOPD – acute 
578 exacerbation of chronic obstructive pulmonary disease. 
579 Figure 2: Linear regression between changes in the A) Functional Assessment of Chronic 
580 Illness Therapy Fatigue Subscale (FACIT-FS) and changes in the St George’s Respiratory 
581 Questionnaire (SGRQ)-impact; B) FACIT-FS and changes in the SGRQ-total score; C) 
582 modified-FACIT-FS and changes in the SGRQ-impact; D) modified-FACIT-FS and 
583 changes in the SGRQ-total score (n=53).
584 Figure 3: Plots of the pooled minimal clinically important differences (MCID) for the: A) 
585 Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-FS); B) 
586 modified-FACIT-FS; C - Checklist of individual strength fatigue subscale (CIS-FS). The 
587 plots represent the MCID estimates derived in this study, and where appropriated the 
588 estimates include the 95% confidence interval (n=53). AECOPD – acute exacerbation of 
589 chronic obstructive pulmonary disease; SGRQ – St. George Respiratory Questionnaire; SD 
590 – standard deviation; SEM – standard error of measurement; MDC – minimal detectable 
591 change.
592
593
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1 ABSTRACT:
2 Background: Fatigue is a burdensome and prevailing symptom in patients with chronic 
3 obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) improves fatigue 
4 however, interpreting when such improvement is clinically relevant is challenging. Minimal 
5 clinically important differences (MCIDs) for instruments assessing fatigue are warranted to 
6 better tailor PR and guide clinical decisions. We estimated MCIDs for the functional 
7 assessment of chronic illness therapy-fatigue subscale (FACIT-FS), the modified-FACIT-
8 FS and the checklist of individual strength-fatigue subscale (CIS-FS), in patients with COPD 
9 after PR.
10 Methods: Data from patients with COPD who completed a 12-weeks community-based PR 
11 programme were used to compute the MCIDs. The pooled MCID was estimated by 
12 calculating the arithmetic weighted mean, resulting from the combination of anchor (weight-
13 2/3) and distribution-based (weight-1/3) methods. Anchors were patients’ and 
14 physiotherapists’ global rating of change scale, COPD assessment test, St. George’s 
15 respiratory questionnaire (SGRQ) and exacerbations. To estimate MCIDs we used mean 
16 change, receiver operating characteristic curves and linear regression analysis for anchor-
17 based approaches, and 0.5*standard deviation, standard error of measurement 
18 (SEM),1.96*SEM and minimal detectable change for distribution-based approaches.
19 Results: Fifty-three patients with COPD (79%male, 68.4±7.6years, FEV148.7±17.4%predicted) 
20 were used in the analysis. Exacerbations, the SGRQ-impact and the SGRQ-total scores 
21 fulfilled the requirements to be used as anchors. Pooled MCIDs were 4.7 for FACIT-FS, 3.8 
22 for the modified-FACIT-FS and 9.3 for the CIS-FS.
23 Conclusion: The MCIDs proposed in this study can be used by different stakeholders to 
24 interpret PR effectiveness.
25 Clinical trial registration: NCT03799666 on ClinicalTrials.gov
26 Keywords:  *Exercise *Interpretability *Outcome measurement *Health status * clinical 
27 decision-making
28
29
30
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3
31 INTRODUCTION: 
32 Chronic obstructive pulmonary disease (COPD) is highly symptomatic.1 Although dyspnoea 
33 is the symptom most commonly reported,1 fatigue has been recognised to affect around 50 
34 to 70% of patients with COPD.2,3 Fatigue is a multi-dimensional and disabling symptom 
35 defined as an overwhelming feeling of tiredness and drain of energy.4,5 It negatively 
36 influences patients’ physical, cognitive, psychological and social functioning,4,6-8 leads to 
37 limited daily functioning and reduced health-related quality of life.3,8-10 Fatigue severely 
38 impacts on COPD prognosis, being closely associated to exacerbations rate and an 
39 independent predictor of mortality.10-13 
40 Pulmonary rehabilitation (PR) is a fundamental intervention to manage COPD, with known 
41 cost-effectiveness in fatigue reduction.1,8,14-18 However, the interpretation of PR effects on 
42 fatigue remains a challenge due to the lack of well-established minimal clinically important 
43 differences (MCID) of patient-reported outcome measures (PROMs) that assess fatigue.19-
44 21 MCIDs establish thresholds for clinical meaningfulness, i.e., determine which is the 
45 smallest change in a PROM score that will be perceived as an important improvement for 
46 the patient.19,21,22 MCIDs for fatigue-related PROMs will establish a therapeutic threshold 
47 for PR effectiveness and guide clinical decision-making in the management of patients with 
48 COPD.23-25 A wide variety of methods can be used to estimate MCIDs,23,24,26-28 among which 
49 the following two are distinguished: anchor-based methods, which use an external criterion 
50 (e.g., self-reported opinion or clinicians judgements) to provide clinical meaning;27,29 and 
51 distribution-based methods, that add statistical significance by expressing change scores 
52 according to the sample variability and measurement precision.27,30 Although the importance 
53 of anchor-based approaches in comparison to distribution methods has been advocated,23,27 
54 both methodologies present limitations, thus, the recommendation is to triangulate both 
55 methods.27,28 
56 We determined the MCID of three PROMs commonly used to assess fatigue in patients with 
57 COPD, the functional assessment of chronic illness therapy fatigue subscale (FACIT-FS),31 
58 the modified-FACIT-FS32 and the checklist of individual strength fatigue subscale (CIS-
59 FS).4
60 MATERIALS AND METHODS: 
61 Study design and population 
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4
62 This observational prospective study is integrated into a larger trial (NCT03799666), with 
63 ethical approval from the Ethics Committee for Health of the Administração Regional de 
64 Saúde do Centro (Ref. 73/2016) and from the National Committee for Data Protection (no. 
65 7295/2016). All participants signed an informed consent.
66 Patients diagnosed with COPD,1 who completed a 12-weeks community-based PR 
67 programme, between January and July 2019, in 6 primary healthcare centres and in the 
68 Respiratory Research and Rehabilitation laboratory (Lab3R) at the School of Health 
69 Sciences, University of Aveiro, were included. Exclusion criteria included the presence of 
70 other respiratory diseases or significant cardiovascular, neurological or musculoskeletal 
71 disease which limited patients’ participation in PR. The PR programme consisted of exercise 
72 training sessions twice a week and education and psychosocial sessions once every two 
73 weeks, with two of them targeting specifically the management of fatigue: i) management 
74 of symptoms and strategies of energy conservation and ii) sleep disorders and management 
75 of stress and anxiety. Further information regarding the intervention and education and 
76 psychosocial contents has been previously published.33,34 Only participants who attended at 
77 least 8 of the 12-weeks of PR were included.1 
78 A sample size of at least 50 participants is required to determine the MCID of a PROM.35,36  
79 Since the drop-out rates during PR programmes range from 20 to 30%,37,38 we aimed to 
80 recruit 65 participants. 
81 Data collection
82 Sociodemographic, anthropometric and clinical data were obtained to characterise the 
83 sample. The Charlson Comorbidity Index39 was used to score the severity of comorbid 
84 conditions. The remaining outcome measures were assessed before (T0) and after PR (T1). 
85 Impact of the disease was assessed with the COPD assessment test (CAT)40 and health-
86 related quality of life with the St. George’s respiratory questionnaire (SGRQ).41
87 The FACIT-FS is a multi-dimensional 13-item questionnaire assessing tiredness, weakness 
88 and difficulty in handling daily activities due to fatigue, over the previous 7 days.12,31 Each 
89 item has a 5-points Likert scale (from “not at all” to “very much”), and scores range from 0 
90 to 52, with higher scores indicating less fatigue.31,42 Patients scoring below the cut-off point 
91 of 43 points were considered to have clinically relevant fatigue.43 The FACIT-FS has shown 
92 high internal consistency32 and test-retest reliability,44 and good concurrent and 
93 discriminating validity32,45 in patients with COPD. A modified version of FACIT-FS, 
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94 adapted to patients with COPD, has been proposed.32 The modified-FACIT-FS  has 9 items 
95 and scores range from 0 to 36 points.32 
96 The CIS-FS4 was used to evaluate the fatigue experience. The CIS-FS is an 8-statements 
97 self-reported measure, with a period recall of two weeks, where each item is scored on a 7-
98 point Likert scale.4 Total scores range from 8 to 56, and 3 subgroups can be categorised: 
99 normal fatigue (≤26 points), mild fatigue (27-35 points) and severe fatigue (≥36 points).46 
100 The CIS-FS has shown high internal consistency and test-retest reliability, good concurrent 
101 and criterion validity46 and ability to detect change in subjective fatigue.2,47-49 
102 The global rating of change scale (GRC) is a simple, retrospective and numerical analogue 
103 scale50 that asks patients to make a judgement regarding their perceived fatigue after PR and 
104 to compare it with the initial assessment. It was administered only after PR, using an 11-
105 point Likert scale ranging from -5 (much worse) to +5 (much better) (supplementary 
106 material).50
107 Statistical analysis
108 Data analysis was performed with IBM SPSS Statistics 24, and plots were designed with 
109 GraphPad Prism 7 and MetaXL 5.3. Paired t-test were used to test significance of changes 
110 in PROMs from T0 to T1. Floor and ceiling effects were checked and deemed inexistent if 
111 less than 15% of the patients scored at the bottom or top of the questionnaires.51 Outliers 
112 were checked, i.e., inspection of extreme points in plotted graphs from the studied variables, 
113 and excluded if present.52 
114 MCIDs were established through the combination of anchor-based and distribution-based 
115 methods for the FACIT-FS, modified-FACIT-FS and CIS-FS. 24,27 
116 Anchor-based methods
117 The following measures were explored for their adequacy to be used as anchors:
118 i) Patients referencing: the GRC was used to classify patients’ perception of change in 
119 fatigue. Significant changes were considered for the GRC higher than 2.50
120 ii) Physiotherapists referencing: the GRC was used to ask the physiotherapists running 
121 the PR programmes about their perception regarding patients’ changes in fatigue. 
122 Significant changes were considered for the GRC higher than 2.50
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123 iii) Questionnaire referencing: changes in CAT and SGRQ were used as external 
124 criterions to determine the CIS-FS and FACIT-FS MCIDs. The MCIDs for the CAT 
125 (2 points)53 and for the SGRQ (4 points)54 were used to distinguish between patients 
126 who improved from those who did not improve their fatigue symptoms.
127 iv) Criterion referencing: AECOPD are considered major health events1 and are 
128 correlated to worse PROM scores, thus, their occurrence during PR was used as an 
129 anchor.25 
130 Correlations between the potential anchors and each fatigue-related PROM were explored 
131 using Pearson or point-biserial correlation coefficients. For patients, physiotherapists and 
132 questionnaire referencing, significant and moderate correlations (r≥0.3) were established as 
133 criteria to proceed with the calculation of the MCIDs using anchor-based methods.27 Then, 
134 three statistical methods were used to compute the MCID: i) mean change in the PROM 
135 score (between T1 and T0) for patients who reached the anchor MCID;22,24 ii) receiver 
136 operating characteristic (ROC) curves and the corresponding likelihood ratio (LR) 
137 (interpreted according to McGee),55 calculated with the dichotomous variable, i.e., those 
138 who achieved or not the MCID of the anchor [an area under the curve (AUC) was considered 
139 adequate if statistically significant and greater than 0.7; the optimal cut-off point was set as 
140 the point where specificity and sensitivity were both optimised, i.e., the closest point to the 
141 left corner]55 and iii) linear regression analysis, using the Enter method, where the change 
142 in the fatigue PROMs was used as the dependent variable, and the change score of the anchor 
143 was considered the independent variable. 
144 Regarding criterion referencing, the presence of significant differences in fatigue baseline 
145 scores between patients who experienced an exacerbation and those who did not was the 
146 criteria to proceed with the MCID calculation. Independent t-tests were used to explore 
147 differences and when present, the absolute difference was considered the MCID25,56 
148 Afterwards, ROC statistics were used to test the PROMs discriminating ability to anticipate 
149 the occurrence of an AECOPD. 
150 Distribution-based methods
151 The distribution-based methods used to determine the MCID were: 
152 i) 0.5 times standard deviation (SD) at the baseline;26
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153 ii) standard error of measurement (SEM), calculated as SEM=SDbaseline√(1-r), where 
154 r is the test-retest reliability coefficient;21
155 iii) 1.96 times SEM;23,28
156 iv) minimal detectable change (MDC),26,57 calculated as MDC=1.96*SEM*√2;
157 v) effect size (ES) through ES=(meanafterPR–meanbaseline)/
158 . The ES thresholds were ≥0.2 for small, ≥0.5 for (SD2afterPR + SD2baseline)/2
159 medium and ≥0.8 for large.57 
160 Pooled MCID
161 There are no guidelines on how to weight anchor- and distribution-based approaches, 
162 therefore, based on the authors’ best judgement and on previous work,58,59 we decided to 
163 attribute 2/3 to anchor-based and 1/3 to distribution-based methods. To pool the final MCID 
164 we calculated the arithmetic weighted mean. The MCIDs generated from the different 
165 methods were entered into the MetaXL 5.3 to create the MCIDs’ plots. The percentage of 
166 change of the pooled MCID in relation to the fatigue-related PROMs was also calculated. 
167 Previous studies have suggested that MCIDs which fell within the range of 6 to 10% of the 
168 total score,24 correspond to the desirable ES for MCID, i.e., 0.2 to 0.5.24,27,57 The ES derived 
169 from the pooled MCID were calculated using the ESformula: MCIDES = 
170 MCIDpooled/ . (SD2afterPR + SD2baseline)/2
171 RESULTS: 
172 A flow diagram of the recruited and included patients is provided in Figure 1.
173 (Please insert Figure 1 here)
174 After outliers’ assessment, five participants were excluded since in boxplot analysis, they 
175 presented extreme scores in FACIT-FS and SGRQ-total change scores. Baseline 
176 characteristics of the included sample and of the outliers were not statistically different 
177 (p>0.05). Included patients and drop-outs presented similar baseline characteristics (Table 
178 1).
179 (Please insert Table 1 here)
180 After PR, significant improvements were found in all PROMs (Table 2): 86.8% of 
181 participants perceived improvements in their fatigue (GRC: 3.0 [2.0-4.0]) and 
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182 physiotherapists also considered that 86.8% of patients improved (3.0, [2.0-4.0]). No 
183 ceiling/floor effects were found for the FACIT-FS, modified-FACIT-FS and CIS-FS. 
184 (Please insert Table 2 here)
185 Minimal clinically important differences
186 Anchor-based methods
187 Changes in the FACIT-FS and modified-FACIT-FS correlated significantly and moderatly 
188 with changes in the SGRQ-total (r=-0.330; r=-0.439), -impact scores (r=-0.409; r=-0.474) 
189 and with AECOPD (rpb=-0.277; rpb=-0.274). A significant correlation between changes in 
190 modified-FACIT-FS and SGRQ-ativities scores was also present, however, it was not 
191 considered since it was inferior to 0.3 (r=-0.288). Changes in the CIS-20 FS correlated only 
192 with AECOPD (rpb=0.323), therefore, the remaining anchors were not further analysed. All 
193 correlations are presented in e-Table 1.
194 Questionnaire referencing
195 MCIDs for the FACIT-FS derived from the mean change methods were 5.7 points using the 
196 SGRQ-impact and 4.9 points using the SGRQ-total whereas for the modified-FACIT-FS 
197 were 4.4 points using SGRQ-impact and 3.9 using SGRQ-total (Table 3). Mean change 
198 results for all the explored anchors can be found in e-Table 2 and e-Table 3.
199 The AUCs generated for either FACIT-FS and modified-FACIT-FS using the SGRQ-
200 impact/total did not fulfill the requirements, thus, ROC statistics were not used. 
201 Using linear regression, the estimated MCIDs for the FACIT-FS were 3.4 (SGRQ-impact) 
202 and 3.2 (SGRQ-total) points and  for the modified-FACIT-FS were 2.3 points using SGRQ-
203 impact and 1.9 points using SGRQ-total (Figure 2). 
204 (Please insert Figure 2 here)
205 Criterion Referencing
206 Mean change method applied for criterion referencing yielded a MCID of 6.4 (95%CI 1.2 
207 to 11.6; p=0.044) points for the FACIT-FS; of 4.7 (95%CI 0.1 to 9.3; p=0.047) points for 
208 the modified-FACIT-FS; and of 9.6 points (95%CI 2.5 to 16.0; p=0.018) for CIS-FS (e-
209 Table 4).
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9
210 The AUCs generated for all fatigue PROMs were able to distinguish between patients who 
211 experienced an AECOPD and those who did not (FACIT-FS: AUC=0.71; 95%CI 0.58 to 
212 0.85; p=0.021/ modified-FACIT-FS: AUC=0.73; 95%CI 0.59 to 0.86; p=0.015/ CIS-FS: 
213 AUC=0.72; 95%CI 0.57 to 0.87; p=0.019)(e-Figure 1). According to the ROC analysis, 
214 patients scoring below 32 points on the FACIT-FS or above 43.5 points on the CIS-FS had 
215 a LR of 2.2 (sensitivity=68%; specificity=69%). Cut-off point found for the modified-
216 FACIT-FS  was 19.5 points, with a LR of 2.5 (sensitivity=73%; specificity=69%).
217 Distribution-based methods
218 Distribution-based methods for the FACIT-FS, modified-FACIT-FS and CIS-FS are 
219 presented in Table 3. 
220 Pooled MCID
221 Pooled MCIDs were  4.7 points for the FACIT-FS,  3.8 for the modified-FACIT-FS and  9.3 
222 points for CIS-FS (Figure 3). Overall MCID pooled statistics are presented in Table 3.
223 (Please insert Figure 3 here)
224 (Please insert Table 3 here)
225 DISCUSSION:
226 This study found pooled MCIDs of 4.7 points for the FACIT-FS, 3.8 points for the modified-
227 FACIT-FS and 9.3 points for CIS-FS, following a PR programme in patients with COPD.
228 Nearly 80% of our sample reported fatigue symptoms, surpassing the 50 to 70% reported in 
229 previous literature.2,3,11,60 These findings call for attention to the tremendous impact and 
230 burden of fatigue in COPD, emphasising the importance of its routine assessment and the 
231 need for tailoring therapies to target fatigue. Our results showed significant improvements 
232 in FACIT-FS, modified-FACIT-FS and CIS-FS following a community-based-PR 
233 programme, highlighting the effectiveness and the key role of this comprehensive 
234 intervention in managing fatigue.2,16,18
235 MCIDs are recognised to be disease-specific23 and, to our best knowledge, this is the first 
236 study to establish MCIDs for both FACIT-FS versions and CIS-FS in patients with COPD. 
237 For the original-FACIT-FS, the MCID has been previously determined in other populations, 
238 with our estimation being similar to the one reported for rheumatoid arthritis (i.e., 3-4 
239 points),61 but smaller than the estimated for the systemic lupus erythematosus (i.e., 5.9 
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240 points).62 These differences are likely to be explained by the dissimilarities among 
241 populations and methodologies (longitudinal and within-patient differences vs. cross-
242 sectional and between patient-differences). Although a MCID of 10 points has been reported 
243 for the CIS-FS,2 no information, or reference, regarding its calculation is provided limiting 
244 comparisons between studies. 
245 MCIDs were computed using different approaches and integrating a wide range of anchor- 
246 and distribution-based methods. It is known that MDC yield large estimates and tend to 
247 overestimate MCIDs.23,63 Previous research have classified MDC as a benchmark for 
248 moderate to large change, warning that MCIDs could be smaller than MDC.23,63 These 
249 discrepancies enhance the need to combine anchor-based methods (weighting 2/3), which 
250 provide clinical meaning, and distribution-based methods (weight 1/3), which add statistical 
251 significance,23,27 as previously recommended.24,27 
252 Within the multiple anchor-based approaches used, only the SGRQ and the occurrence of 
253 AECOPD fulfilled the criterion to proceed with the MCID calculation, with the latter 
254 yielding larger estimations. Regarding either patients’ or physiotherapists’ GRC, it is 
255 noticeable that most patients/physiotherapists perceived improvements in fatigue, thus the 
256 variability of data was reduced, which is known to limit the power of correlations.64 
257 Moreover, another hypothetical reason for the lack of correlations is the well-known recall 
258 and administration bias associated to  the GRC.24,50,65 Fatigue is a complex, multifaceted and 
259 dynamic phenomenon,5 and PROMs focus specifically on the perceived fatigability, thus, 
260 do not fully portray fatigue. This complexity might also have impacted our correlations. 
261 Disparities among physiotherapists’ GRC and the fatigue PROMs sustain the poor 
262 physician-patient concordance previously stated.66 
263 The impact of fatigue on health status and quality of life is irrefutable.2,10,11,32 Previous 
264 associations between these outcomes2,32 highlight the importance of the SGRQ to determine 
265 fatigue-related MCIDs. The absence of correlations among the CIS-FS and the SGRQ 
266 dimensions might be explained by the conceptual differences between the fatigue PROMs. 
267 While the CIS-FS focuses specifically on the subjective experience of fatigue,4 FACIT-FS 
268 integrates two components of fatigue: experience of fatigue and impact of fatigue,67 
269 probably, the latter is more intimately related to the SGRQ impact-dimension and 
270 consequently, to the total-dimension.32 CAT assesses several respiratory symptoms, and 
271 only one item is directly related to fatigue (energy). Instead of the CAT-total score, which 
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272 failed to capture changes in fatigue, it would have been interesting to use as an anchor the 
273 CAT-energy question. However, this was not possible, as the MCID for single CAT-items 
274 is not established.
275 Similar to previous research,11,12 our study, further established the role of fatigue as a 
276 prognostic measure for AECOPD, showing that patients scoring below 32 points on the 
277 FACIT-FS, below 19.5 points on the modified-FACIT-FS and over 43.5 on the CIS-FS have 
278 around 15% increased probability of having and exacerbation (LR from 2.2 to 2.5).55 
279 According to our results, all fatigue PROMs used have similar prediction abilities to 
280 distinguish between patients who experienced an AECOPD from those who did not. Thus, 
281 these tree questionnaires seem to be equally valuable to predict a patient’s exacerbation risk 
282 and to adjust the PR programme accordingly (e.g., by further enhancing the education on 
283 prevention of exacerbations).68 
284 Nevertheless, this study also presents some limitations that should be acknowledged. First, 
285 the PROMs used as referencing questionnaires, i.e., CAT and SGRQ, do not assess fatigue 
286 specifically. To the authors’ best knowledge, the chronic respiratory questionnaire is the 
287 only PROM that specifically targets fatigue and has a MCID established for patients with 
288 COPD,69 however it could not be used in this study, as it is not culturally adapted for the 
289 Portuguese population. Second, our sample was mainly composed by GOLD B patients, 
290 therefore, the external validity of our study might be reduced. MCIDs should correspond to 
291 a 6 to 10% change in the PROMs scale and to an ES between 0.2 to 0.5.24,27,57 The MCID 
292 found for CIS-FS corresponded to an ES of 0.7 and 19% change, thus, it may have been 
293 overestimated. It is worth noting that, even if nor ceiling or floor effects were present, our 
294 sample presented high baseline levels of fatigue, leading to greater room for improvement 
295 with treatment, and thus higher MCIDs.23,24,26,70 The fact that only the criterion anchor and 
296 distribution-based methods were used to compute the MCID for CIS-FS, could have also 
297 contributed to overestimate the result. Our overall sample size was not enough to perform 
298 sub-analysis according to baseline fatigue or disease severity. This study included 
299 exclusively the physiotherapists GRC, thus providing a limited insight into patients’ fatigue, 
300 as PR is a multidisciplinary intervention. Future studies including a Delphi Method would 
301 be useful to integrate different stakeholders’ perspectives.27 A consensus between 
302 worldwide experts in MCIDs would be extremely helpful to confidently establish the 
303 weights assigned to either anchor- and distribution-based approaches. More studies with 
304 larger samples are required to control for these factors and further validate our estimations. 
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305 CONCLUSIONS:
306 The present study determined that changes of 4.7 on the FACIT-FS, 3.8 on the modified-
307 FACIT-FS and 9.3 on the CIS-FS represent clinically relevant improvements in fatigue after 
308 PR in patients with COPD. These MCIDs should be interpreted accordingly to each patient 
309 specificities and incorporated into clinical practice to guide different stakeholders in the 
310 decision-making process. 
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527 Table 1: Sample characterisation (n=70).
Characteristics Patients included
n=53 (75.7%)
Drop-outs
n=17 (24.3%)
p-value
Age, years 68.4±7.6 67±11.3 0.568
Gender, male n (%) 42 (79.2) 12 (70.6) 0.460
BMI, kg/m2 25.6±4.3 27.2±4.8 0.217
Smoking status, n (%)
Current
Former
Never
9 (17)
35 (66)
9 (17)
6 (35.3)
7 (41.2)
4 (23.5)
0.638
Packs/year 40.5 [26.4-64] 22 [13.3-50.4] 0.057
Exacerbations/year1, n 1 [0-1] 1 [0-2] 0.139
AECOPD hospitalisations1, n (%) 4 (7.5) 4 (23.5) 0.072
Duration of hospitalisations, days 8.2±7.1 10.4±9.4 0.606
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COPD-related emergencies1, n (%) 18 (34) 7 (41.2) 0.589
Lung function (post-bronchodilator)
FEV1, l 1.3±0.5 1.4±0.5 0.404
FEV1, %predicted 48.1±17.4 56.5±19.6 0.101
FEV1/FVC, % 49.1±14.1 55.9±13 0.077
GOLD stages, n (%)
I
II
III
      IV
5 (9.4)
19 (35.8)
23 (43.4)
6 (11.3)
2 (11.8)
7 (41.2)
7 (41.2)
1 (5.9)
0.905
GOLD groups, n (%)
A
B
C
D
8 (15.1)
34 (64.2)
0 (0)
11 (20.8)
4 (23.5)
6 (35.3)
0 (0)
7 (41.2)
0.106
CCI, n (%) 0.389
Mild (1-2 points) 7 (13.2) 1 (5.9)
Moderate (3-4 points) 30 (56.6) 8 (47.1)
Severe (≥5 points) 16 (30.2) 8 (47.1)
Medication, n (%) 
Bronchodilators
SABA 7 (13.2) 1 (5.9) 0.360
SAMA 2 (3.8) 0 (0) 0.393
LABA 6 (11.3) 5 (29.4) 0.102
LAMA 16 (30.2) 10 (58.8) 0.065
LAMA/LABA combination 16 (30.2) 4 (23.5) 0.597
ICS 9 (17) 1 (5.9) 0.226
ICS/LABA combination 23 (43.3) 7 (41.2) 0.872
ICS/LABA/LAMAcombination 1 (1.9) 0 (0.0) 0.273
LTRA 2 (3.8) 2 (11.8) 0.217
Xanthines 10 (18.9) 2 (11.8) 0.499
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Expectorants 5 (9.4) 1 (5.9) 0.649
Antibiotics 1 (1.9) 0 (0) 0.606
mMRC, points 2 [1-3] 2 [1-3] 0.733
CAT, points 16.9±7.5 16.2±9.2 0.736
SGRQ, points
Symptoms 55±20.5 45.8±20.1 0.112
Activities 64.8±20.9 50.3±27.8 0.060
Impact 36.6±19.8 27.8±19.1 0.114
Total 48.2±18.6 37.7±19.8 0.050
FACIT-FS, points 33.3±10 37.7±12.8 0.151
No relevant fatigue (>43), n (%) 19 (17) 5 (29.4)
Relevant fatigue (≤43), n (%) 44 (83) 12 (70.6)
0.214
Modified-FACIT-FS 21.2±7.4 22.7±7.7 0.496
CIS-FS, points 36.9±12.8 32.7±13.9 0.258
Normal fatigue (≤26), n (%) 9 (17) 6 (35.3)
Mild fatigue, (27-35), n (%) 12 (22.6) 5 (29.4)
Severe fatigue (≥36), n (%) 32 (60.4) 6 (35.3)
0.153
528 Notes: Values are presented as mean±standard deviation or median [interquartile range], unless otherwise stated. 1in the past-year; * 
529 p<0.05
530 Legend: PR – pulmonary rehabilitation; BMI – body mass index; AECOPD – acute exacerbation of chronic obstructive pulmonary 
531 disease; FEV1 – forced expiratory volume in one second; FVC – forced vital capacity; GOLD - Global Initiative for Chronic Obstructive 
532 Lung Disease; CCI – Charlson comorbidity index; SABA – short-acting beta-agonists; SAMA – short-acting muscarinic antagonist; 
533 LABA – long-acting beta-agonists; LAMA – long-acting muscarinic antagonist; ICS – inhaled corticosteroid; LRTA – leukotriene receptor 
534 antagonist; mMRC – modified medical research council questionnaire; CAT – COPD assessment test; SGRQ – St George’s Respiratory 
535 Questionnaire; FACIT-FS - Functional assessment of chronic illness therapy fatigue subscale; CIS-FS - Checklist of individual  strength 
536 fatigue subscale.
537
538
539
540
541
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542 Table 2: Patient-reported outcome measures before and after the community-based 
543 pulmonary rehabilitation programme (n=53).
PROM (points) Baseline Post-PR △ 95% CI p-value ES
CAT 16.9±7.5 13.0±6.9 -3.9±6.7 -5.8 to -2.0 <0.001* -0.54
SGRQ 
Symptoms 55±20.5 41.1±20.5 -13.9±21.5 -19.8 to -7.9 <0.001* -0.68
Activities 64.8±20.9 57.8±23.5 -7.0±11.6 -10.2 to -3.8 <0.001* -0.31
Impact 36.6±19.8 30.4±18.7 -6.2±12.0 -9.5 to -2.8 <0.001* -0.32
Total 48.2±18.6 40.6±18.1 -7.6±10.4 -10.5 to -4.7 <0.001* -0.41
FACIT-FS 33.3±10 36.9±8.8 3.7±7.1 1.7 to 5.6 <0.001* 0.38
Modified-FACIT-
FS 21.2±7.4 24.0±6.9 2.7±5.5 1.2 to 4.3 0.001 0.38
CIS-20 FS (n=52) 36.9±12.8 31.1±13.4 -5.8±10.2 -8.7 to -3.0 <0.001* -0.44
544 Notes: Values are presented as mean±standard deviation. *p<0.05
545 Legend: PROM – Patient-reported outcome measure; PR – pulmonary rehabilitation; △ – mean change; ES – Effect sizes: 95%CI – 
546 95% confidence interval; CAT – COPD assessment test; SGRQ – St George’s Respiratory Questionnaire; FACIT-FS – Functional 
547 assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength fatigue subscale.
548
549
550
551
552
553
554
555
556
557
558
559
560
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563 Table 3: Anchor and distribution-based methods used to compute the minimal clinically 
564 important difference of fatigue patient-reported outcome measures.
565
566 Notes: Values are presented as mean and 95% confidence intervals. % of change was computed within each scale range. The MCID ES 
567 are compute as the MCID value divided by the pooled SD.  
568 Legend: FACIT-FS – Functional assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength 
569 fatigue subscale; SGRQ – St George’s Respiratory Questionnaire; ROC – Receiver operating characteristic curves; SD – standard 
570 deviation; SEM – standard error of measurement; MDC – minimal detectable change; ES – effect size; MCID - minimal clinically 
571 important difference.
572
573
574
FACIT-FS Modified-FACIT-
FS
CIS-FS
Mean change 5.7 (3.3 to 8.1) 4.4 (2.4 to 6.4) -
ROC - - -SGRQ-Impact
Linear regression 3.4 (2.1 to 4.7) 2.3 (1.2 to 3.3) -
Mean change 4.9 (2.5 to 7.2) 3.9 (2.0 to 5.9) -
ROC - - -SGRQ-Total
Linear regression 3.2 (1.7 to 4.6) 1.9 (0.7 to 3.1) -
AECOPD Mean change 6.4 (1.2 to 11.6) 4.7 (0.1 to 9.3) 9.6 (3.2 to 15.9)
0.5SD 4.3 3.7 6.4
SEM 2.6 2.2 5.0
1.96SEM 5.1 4.4 9.7
MDC 7.2 6.2 13.8
ES 0.42 0.38 -0.44
Pooled MCID 4.7 3.8 9.3 
% of change 9.1 10.6 19.3
MCID ES 0.5 0.5 0.7
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575 FIGURE LEGEND: 
576 Figure 1: Flow diagram of participants recruited and included in the study. COPD – Chronic 
577 obstructive pulmonary disease; PR – pulmonary rehabilitation; AECOPD – acute 
578 exacerbation of chronic obstructive pulmonary disease. 
579 Figure 2: Linear regression between changes in the A) Functional Assessment of Chronic 
580 Illness Therapy Fatigue Subscale (FACIT-FS) and changes in the St George’s Respiratory 
581 Questionnaire (SGRQ)-impact; B) FACIT-FS and changes in the SGRQ-total score; C) 
582 modified-FACIT-FS and changes in the SGRQ-impact; D) modified-FACIT-FS and 
583 changes in the SGRQ-total score (n=53).
584 Figure 3: Plots of the pooled minimal clinically important differences (MCID) for the: A) 
585 Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-FS); B) 
586 modified-FACIT-FS; C - Checklist of individual strength fatigue subscale (CIS-FS). The 
587 plots represent the MCID estimates derived in this study, and where appropriated the 
588 estimates include the 95% confidence interval (n=53). AECOPD – acute exacerbation of 
589 chronic obstructive pulmonary disease; SGRQ – St. George Respiratory Questionnaire; SD 
590 – standard deviation; SEM – standard error of measurement; MDC – minimal detectable 
591 change.
592
593
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Figure 1: Flow diagram of participants recruited and included in the study. COPD – Chronic obstructive 
pulmonary disease; PR – pulmonary rehabilitation; AECOPD – acute exacerbation of chronic obstructive 
pulmonary disease. 
130x114mm (144 x 144 DPI) 
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Figure 2: Linear regression between changes in the A) Functional Assessment of Chronic Illness Therapy 
Fatigue Subscale (FACIT-FS) and changes in the St George’s Respiratory Questionnaire (SGRQ)-impact; B) 
FACIT-FS and changes in the SGRQ-total score; C) modified-FACIT-FS and changes in the SGRQ-impact; D) 
modified-FACIT-FS and changes in the SGRQ-total score (n=53). 
198x177mm (300 x 300 DPI) 
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Figure 3: Plots of the pooled minimal clinically important differences (MCID) for the: A) Functional 
Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-FS); B) modified-FACIT-FS; C - Checklist of 
individual strength fatigue subscale (CIS-FS). The plots represent the MCID estimates derived in this study, 
and where appropriated the estimates include the 95% confidence interval (n=53). AECOPD – acute 
exacerbation of chronic obstructive pulmonary disease; SGRQ – St. George Respiratory Questionnaire; SD – 
standard deviation; SEM – standard error of measurement; MDC – minimal detectable change. 
190x275mm (96 x 96 DPI) 
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Supplementary material
Global rating of change scale for patients 
“Regarding fatigue, how would you describe your tiredness/lack of energy at this 
moment, in comparison to the day you started the pulmonary rehabilitation programme?”
      Much worse                                                            No change                                            Much better
Global rating of change scale for physiotherapists 
“Regarding your patient’s fatigue, how would you describe the patient's tiredness/lack of 
energy at this moment, in comparison to the day she/he started the pulmonary 
rehabilitation programme?” 
       Much worse                                                            No change                                            Much better
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e-Figure 1 - Receiver operating characteristic curves to discriminate between patients 
with chronic obstructive pulmonary disease who experienced an acute exacerbation 
(AECOPD) from those who did not using the: A) Functional Assessment of Chronic 
Illness Therapy Fatigue Subscale (FACIT-FS) baseline scores; B) modified FACIT-FS 
baseline scores and C) Checklist of individual strength fatigue subscale (CIS-FS) baseline 
scores. (n=53). AUC – area under the curve.
e-Table 1: Correlations between the anchors and changes in the patient-reported outcome 
measures.
∆ FACIT – FS (n=53)
∆ modified 
FACIT – FS 
(n=53)
∆ CIS-20 FS (n=52)
r p-value r p-value r p-value
Patient’s GRC 0.025 0.858 0.059 0.678 -0.084 0.553
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Physiotherapist’s 
GRC 0.140 0.318
0.098 0.487 -0.014 0.923
∆ CAT 0.104 0.459 -0.019 0.894 -0.100 0.482
∆SGRQ
Symptoms -0.055 0.697 -0.141 0.315 -0.148 0.296
Activities -0.172 0.217 -0.288 0.037* 0.038 0.788
Impact -0.409 0.002* -0.474 <0.001* 0.137 0.332
Total -0.330 0.016* -0.439 0.001* 0.043 0.760
AECOPD rpb = -0.277# 0.044* rpb = -0.274# 0.047* rpb = 0.323# 0.018*
Notes: correlations were calculated using Pearson’s (r) or point biserial correlation (rpb) coefficients. # - correlations were 
computed using CIS-FS, FACIT-FS and modified FACIT-FS baseline scores; * p<0.05
Legend: ∆ – mean change; FACIT-FS – Functional assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of 
individual strength fatigue subscale; r – Pearson’s correlation; GRC – Global rating of change scale; CAT – COPD assessment test; 
SGRQ – St George’s Respiratory Questionnaire; AECOPD – acute exacerbations of chronic obstructive pulmonary disease. 
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e-Table 2: FACIT-FS and modified FACIT-FS mean scores at baseline and after community-based pulmonary rehabilitation, according to the anchor’s cut-offs.
FACIT – FS (n=53) modified FACIT-FS (n=53)
n, (%) Baseline Post-PR ∆ 95% CI p-value Baseline Post-PR ∆ 95% CI p-value
≥2 46 (86.8) 33.2±10.1 37.2±8.6 4.0±6.6 2.0 to 5.9 21.2±7.4 24.1±6.9 2.8±5.5 1.2 to 4.5
Patient’s GRC
<2 7 (13.2) 33.7±9.9 37.0±9.9 3.3±7.1 -3.3 to 9.9
0.805
21.1±7.9 23.3±7.2 2.1±6.2 -3.6 to 7.9
0.762
≥2 46 (86.8) 33.0±10.4 37.2±8.8 4.2±6.8 2.2 to 6.2 21.0±7.7 24.1±7.0 3.2±5.6 1.4 to 4.8Physiotherapist’s 
GRC <2 7 (13.2) 35.0±7.0 36.6±8.4 1.7±5.3 -3.3 to 6.6
0.340
23.0±5.3 23.3±6.8 0.3±3.9 -3.3 to 3.9
0.213
≥2 38 (71.7) 33.3±10.4 37.2±9.3 3.9±6.6 1.8 to 6.1 21.1±7.8 24.1±7.5 3.1±5.6 1.2 to 4.9
∆ CAT
<2 15 (28.3) 33.3±9.1 37.1±6.9 3.8±6.9 0.0 to7.7
0.967
21.7±6.7 23.6±5.4 1.9±5.4 -1.1 to 4.9
0.514
≥4 33 (62.3) 31.4±10.4 36.1±9.4 4.7±6.6 2.3 to 7.0 19.7±7.5 23.2±7.6 3.5±5.8 1.4 to 5.6Symptoms
<4 20 (37.7) 36.4±8.6 39.0±7.0 2.6±6-6 -0.5 to 5.8
0.284
23.7±6.6 25.2±5.6 1.5±4.8 -0.7 to 3.7
0.208
≥4 32 (60.4) 33.6±10.3 38.1±9.3 4.5±7.4 1.9 to 7.2 21.3±7.8 25.1±7.4 3.9±6.0 1.7 to 6.0
Activities
<4 21 (39.6) 32.8±9.7 35.7±7.5 2.9±5.2 0.6 to 5.3
0.392
21.2±7.0 22.2±5.8 1.0±4.3 -0.9 to 3.0
0.063
≥4 30 (56.6) 31.5±10.5 37.2±9.7 5.7±6.3# 3.3 to 8.1 20.2±8.0 24.6±7.5 4.4±5.5# 2.4 to 6.4Impact
<4 23 (43.4) 35.5±8.9 37.1±7.2 1.5±6-3 -1.2 to 4.3
0.021
*
22.6±6.5 23.2±6.1 0.6±4.9 -1.5 to 2.7
0.011*
≥4 36 (67.9) 32.6±10.4 37.5±9.2 4.9±7.0# 2.5 to 7.2 20.5±7.7 24.5±7.3 3.9±5.8# 2.0 to 5.9
∆ 
SG
RQ
Total
<4 17 (32.1) 34.7±9.1 36.6±7.5 1.9±5.2 -0.8 to 4.5
0.122
22.7±6.6 22.9±6.2 0.2±4.0 -1.9- to 2-2
0.019*
Notes: Values are presented as mean ± standard deviation. p-value refers to statistical differences between the mean change variables according to the anchors’ cut-off. * p<0.05. # used as minimal clinically 
important differences.
Legend: FACIT-FS – Functional assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength fatigue subscale; PR – Pulmonary rehabilitation; ∆ – mean change; 95% CI – 95% 
confidence intervals;  GRC – Global rating of change; CAT – COPD assessment test; SGRQ – St George’s Respiratory Questionnaire.
Commented [PR1]:  Para conseguir juntar a esta tabela as 
infos da modified FACIT-FS tive que a dividir…ou seja, a 
CIS-FS aparece numa tabela separada
Commented [AM2R2]:  Não conseguimos mesmo meter 
nem mudando as margens? Isto d efacto não é nada o ideal…
Commented [PR3R2]:  Não consigo mesmo, são 5 
colunas a mais…e acho que não podemos reduzir mais o 
tamanho da letra..
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e-Table 3: CIS-FS mean scores at baseline and after community-based pulmonary rehabilitation, according to the anchor’s cut-offs.
 CIS-20 FS (n=52)
n, (%) Baseline Post-PR ∆ 95% CI p-value
≥2 45 (86.5) 36.8±13.2 30.6±13.6 -6.3±10.8 -9.6 to -3.1
Patient’s GRC
<2 7 (13.5) 37.1±10.7 34.3±12.5 -2.9±4.6 -7.2 to 1.4
0.412
≥2 46 (88.5) 37.3±13.3 31.2±14.0 -6.0±10.7 -9.2 to -2.9Physiotherapist’s 
GRC <2 6 (11.5) 34.1±9.5 29.8±8.3 -4.3±5.7 -10.3 to 1.6
0.704
≥2 37 (71.2) 36.2±12.1 30.4±14.6 -5.9±11.0 -9.6 to -2.2
∆ CAT
<2 15 (28.8) 38.6±14.8 32.9±10.1 -5.7±8.4 -10.4 to -1.1
0.960
≥4 33 (63.5) 39.1±12.1 33.8±14.0 -5.2±10.3 -8.9 to -1.6Symptoms
<4 19 (36.5) 33.3±13.5 26.3±11.0 -6.9±10.3 -11.9 to -2.0
0.561
≥4 32 (61.5) 35.0±13.3 29.9±14.7 -5.1±10.3 -8.8 to -1.4
Activities
<4 20 (38.5) 39.7±11.8 33.0±11.1 -7.0±10.2 -11.8 to -2.2
0.526
≥4 29 (55.8) 37.0±12.5 29.8±15.0 -7.2±11.3 -11.5 to -7.2Impact
<4 23 (44.2) 36.7±13.5 32.7±11.2 -4.1±8.7 -7.8 to -0.3
0.274
≥4 36 (69.2) 36.8±12.0 30.9±14.7 -5.9±11.1 -9.6 to -2.1
∆ 
SG
RQ
Total
<4 16 (30.8) 37.1±14.9 31.4±10.4 -5.8±8.2 -10.2 to -1.5
0.988
Notes: Values are presented as mean ± standard deviation. p-value refers to statistical differences between the mean change variables according to the anchors’ cut-off. * p<0.05. # used as minimal clinically 
important differences
Legend: CIS-20 FS – Checklist of individual strength fatigue subscale; PR – Pulmonary rehabilitation; ∆ – mean change; 95% CI – 95% confidence intervals;  GRC – Global rating of change; CAT – COPD assessment test; 
SGRQ – St George’s Respiratory Questionnaire.
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e-Table 4: Patient-reported outcome measures mean scores at baseline and after 
community-based pulmonary rehabilitation, according to the criterion referencing 
(n=53).
AECOPD
No Yes Mean difference 95% CI p-value
n, (%) 40 (75.5) 13 (24.5)
FACIT-FS 
Baseline 34.8±10.3 28.5±7.1
6.4 1.2 to 11.6 p=0.044*
n, (%) 40 (75.5) 13 (24.5)
modified 
FACIT-FS
Baseline 22.4±7.8 17.7±4.6
4.7 0.1 to 9.3 p=0.047*
n, (%) 40 (75.5) 12 (24.5)
CIS-20 FS 
Baseline 34.5±13.2 44.1±8.4
-9.6 -15.9 to -3.2 p=0.018*
Notes: Values are presented as mean ± standard deviation. * p<0.05
Legend: AECOPD – Acute exacerbation of chronic obstructive pulmonary disease; 95% CI – 95% Confidence intervals; FACIT-FS – 
Functional assessment of chronic illness therapy fatigue subscale; CIS-20 FS – Checklist of individual strength fatigue subscale; 
Page 58 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
Page 59 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
Page 60 of 65
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL
1
Patrícia Rebelo
From: Liesbeth.Nieboer@radboudumc.nl on behalf of Jan.Vercoulen@radboudumc.nl
Sent: 31 de janeiro de 2018 16:43
To: Patrícia Rebelo
Subject: RE: Permission to use CIS-20
Attachments: CIS8R-english.pdf; CIS20R-english.pdf; Information and conditions for use.pdf; 
reference paper CIS20r.pdf
  
  
Dear colleague, 
  
Hereby my permission to use the Checklist Individual Strength. 
  
In the attach you will find related documents. 
  
Best regards, 
  
Dr. Jan Vercoulen 
  
  
  
Van: Vercoulen, Jan  
Verzonden: maandag 29 januari 2018 9:11 
Aan: Nieboer, Liesbeth 
Onderwerp: FW: Permission to use CIS-20 
  
Van: Patrícia Rebelo [mailto:patriciarebelo@ua.pt]  
Verzonden: zondag 28 januari 2018 11:10 
Aan: Vercoulen, Jan 
Onderwerp: Permission to use CIS-20 
Dear Sir/Madam, 
My name is Patrícia Rebelo and I am writing to you on behalf of Professor Alda Marques, who is the coordinator of 
the Respiratory Research and Rehabilitation Laboratory (Lab3R) at School of Health Sciences, University of Aveiro 
Portugal. 
We have currently the need to use the Checklist Individual Strength-20 (CIS-20) in one of our research 
projects. We therefore would like to ask your permission to use the CIS-20 Portuguese version. 
I look forward to hear from you. 
Kind regards, 
Alda Marques 
Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 41055629. 
The Radboud university medical center is listed in the Commercial Register of the Chamber of Commerce under file 
number 41055629. 
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De: Marta Marques
Enviado: 18 de outubro de 2017 12:42
Para: joana.cruz@ua.pt
Assunto: RE: pedido de autorização ­ CIS20­P
Cara Joana Cruz, 
Eu ja nao utilizo este email com regularidade daí o atraso. Por favor utilize o email 
marta.marques@ucl.ac.uk para futuros contactos.
Peço pf.f. para contactar a Prof. Maria Joao Gouveia que também colaborou neste projecto e 
peça para lhe enviar a escala e instruções. Diga que falou comigo.
A escala pode ser utilizada para fins de investigação sem ser necessária autorização, 
agradecemos a citação do artigo e caso obtenha dados úteis para fortalecer a validação da 
escala pode nos comunicar.
Obrigada,
Marta Marques
De: joana.cruz@ua.pt [joana.cruz@ua.pt]
Enviado: sexta-feira, 13 de Outubro de 2017 15:03
Para: Marta Marques
Assunto: FW: pedido de autorização - CIS20-P
Exma. Srª Professora Marta Marques, 
Peço desculpa por estar a enviar novamente mail, mas queria ter a certeza de que recebeu o 
meu mail anterior (que reencaminho abaixo) relativamente à escala CIS20, validada no seu 
artigo de 2013. Estou disponível para falar por telefone, caso seja apropriado: 969196218.
Agradeço desde já a disponibilidade e peço desculpa pelo incómodo.
Os melhores cumprimentos,
Joana Cruz
De: joana.cruz@ua.pt
Enviado: 10 de outubro de 2017 17:29
Para: mmarques@ispa.pt
Assunto: pedido de autorização ­ CIS20­P
Exma. Srª Professora Marta Marques, 
Sou um dos elementos de uma equipa de investigação da Universidade de Aveiro e encontrei o 
seu artigo intitulado “Psychometric Properties of the Portuguese Version of the Checklist of 
Individual Strength (CIS20­P)”, o qual mereceu a minha melhor atenção. Gostaríamos de 
utilizar e validar a escala para a população de pessoas com Doença Pulmonar Obstrutiva 
Crónica (DPOC), no âmbito de uma dissertação de Mestrado (com potencial publicação), pelo 
que gostaríamos de a questionar sobre a possibilidade de nos enviar a escala e o sistema de 
codificação, assim como a autorização para utilização da escala.
Estou disponível para prestar informação adicional.
Agradeço desde já a atenção dispensada. 
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Os melhores cumprimentos,
Joana Cruz 
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P.W. Jones, PhD FRCP
Professor of Respiratory Medicine
Tel. ++44 (0)20 8725 5371 Fax. ++44 (0)20 8725 5955 email pjones@sgul.ac.uk
7 March 2017
To Whom It May Concern:
This is to confirm that St George’s, University of London (St George’s
Hospital Medical School) has given permission for Lab3R, School of Health
Sciences of the University of Aveiro, Portugal, to use the St George’s
Respiratory Questionnaire (SGRQ) in a project entitled “Revitalizing
Pulmonary Rehabilitation (3R)"
Professor Paul Jones, PhD FRCP
Professor of Respiratory Medicine
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Modified Medical Research Council  – does not require authorization. It is available 
and recommend for use by the Portuguese national health authority (Direção-Geral de 
Saúde) 
 
COPD Assessment Test - http://www.catestonline.org – does not require authorization. 
"You may, for personal use and for research purposes, read, view, print download and 
copy the material on this website in accordance with the license to copy for personal use 
conditions stipulated in the legal notices." 
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